Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
CHAPEL HILL, N.C., Feb. 03, 2016 -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 5th Annual Leerink Partners Global Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 8:25 a.m. ET on Wednesday, February 10, 2016 at the Waldorf Astoria in New York.
A live audio webcast and archive of the presentation will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
Contacts: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 [email protected] Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected]
